tiprankstipranks

Analyst Profile

Followed by 305 followers
.
Robert LeBoyer

Robert LeBoyer

Noble Financial
Wall Street Analyst
#4,998 out of 7,963 Wall Street Analysts
#13,035 out of 22,261 experts

Success Rate

23%
33 out of 141 transactions made a profit

Average Return

-0.50%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Robert LeBoyer's trades since 2016 and holding each position for 1 Year would result in 23.40% of your transactions generating a profit, with an average return of -0.5% per rating.

Stock Rating Distribution

184Ratings
89.13% Buy
10.87% Hold
0.00% Sell
Distribution of Robert LeBoyer's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market
CanadaCanadian Market

Best Rating

Stock:
Oramed Pharmaceuticals Inc
(ORMP)
Rating:Buy
Date:Oct 19, 2020 - Oct 19, 2021
Return:+706.30%
The most profitable rating made by Robert LeBoyer

Robert LeBoyer's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
ACADIA Pharmaceuticals
Aug 05, 2016
Hold
Downgraded
$41.00
(144.19% Upside)
2Ratings
0%
-6.70%
Acer Therapeutics
Oct 28, 2016
Hold
Downgraded
3Ratings
0%
-56.15%
Acorda Therapeutics
Feb 02, 2018
Hold
Assigned
3Ratings
0%
-23.30%
Concert Pharma
Feb 02, 2018
Hold
Assigned
3Ratings
0%
-53.35%
ADMS
Adamas Pharmaceuticals
Feb 02, 2018
Hold
Assigned
2Ratings
0%
-43.50%
Lisata Therapeutics
Feb 02, 2018
Hold
Assigned
2Ratings
0%
-53.10%
Corbus Pharmaceuticals
Feb 02, 2018
Hold
Assigned
3Ratings
50%
+95.00%
Qualigen Therapeutics
Feb 02, 2018
Hold
Assigned
2Ratings
0%
-84.30%
Matinas BioPharma
Feb 02, 2018
Hold
Assigned
2Ratings
0%
-30.30%
Rosetta Genomics
Feb 02, 2018
Hold
Assigned
4Ratings
0%
-73.20%
List of latest recommendations made by Robert LeBoyer. Click to expand and see Robert LeBoyer's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >